Clinical Trials in Illinois

Showing 1621-1640 of 19,692 trials

Mucopolysaccharidosis VII Disease Monitoring Program

NCT03604835

The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.

Mucopolysaccharidosis VIIMPS VIIMPS 7+1 more

Ultragenyx Pharmaceutical Inc50 participantsStarted Jan 2018

Orange, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +11 more locations

Active Not RecruitingPhase 3125 miles

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

NCT05389449

This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.

Paroxysmal Nocturnal Hemoglobinuria

Alexion Pharmaceuticals, Inc.80 participantsStarted Oct 2022

Los Angeles, California, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +42 more locations

Mucopolysaccharidosis VII Disease Monitoring Program

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Find Trials by Condition in Illinois

ELEVATE High-Risk PCI Pivotal Study

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Evolut™ EXPAND TAVR II Pivotal Trial

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma

Actinium Therapy for Late-stage Aggressive Sarcomas

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

Improving Medical Decision Making for Older Patients With End Stage Renal Disease